lecanemab

lecanemab
Tradename	Leqembi
Routes of administration	Intravenous infusion
ATC prefix	N06
ATC suffix	DX06
CAS number	1802908-13-2
DrugBank	DB16129
UNII	6S3O2BH62X
Synonyms	BAN2401
Molecular formula	C₂₄₈₈H₃₈₅₄N₆₇₂O₇₁₁S₁₈
Molecular weight	55.2 kDa

lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody designed for the treatment of Alzheimer's disease. It selectively targets and promotes the clearance of soluble amyloid beta protofibrils, which are believed to be a key pathological driver of the neurodegenerative process. The drug is administered via intravenous infusion and received traditional approval from the U.S. Food and Drug Administration in July 2023 following results from the pivotal CLARITY AD clinical trial. Its development and approval represent a significant shift in the therapeutic landscape for Alzheimer's disease, marking the first disease-modifying therapy to gain full regulatory endorsement in decades.

Medical uses

Lecanemab is indicated for the treatment of mild cognitive impairment or mild dementia stage of Alzheimer's disease in adult patients, specifically those with confirmed presence of amyloid beta pathology. Treatment decisions should be guided by appropriate diagnostic evaluations, such as positron emission tomography or cerebrospinal fluid analysis, to verify the presence of amyloid plaques. The therapy is not intended for use in later stages of the disease, such as moderate or severe Alzheimer's dementia, and its safety and efficacy have not been established in other forms of dementia or neurodegenerative disease. Administration requires initiation and supervision by healthcare professionals experienced in the management of dementia.

Mechanism of action

The therapeutic action of lecanemab centers on its high affinity for and selective targeting of soluble amyloid beta protofibrils. These protofibrils are intermediate-sized oligomers considered particularly toxic in the amyloid cascade hypothesis, leading to synaptic dysfunction, neuroinflammation, and ultimately neuronal death. As a monoclonal antibody, lecanemab binds to these protofibrils, facilitating their clearance from the brain through effector cell-mediated phagocytosis and engagement with the body's natural immune system. This mechanism is distinct from earlier antibodies that primarily targeted insoluble amyloid plaques, with the goal of intervening earlier in the pathogenic cascade to slow clinical decline.

Clinical trials

The development program for lecanemab included the pivotal Phase III trial known as CLARITY AD, a multicenter, double-blind, placebo-controlled study conducted across sites in North America, Europe, and Asia. Earlier phase studies, including Study 201 and the Phase IIb trial BAN2401-G000-201, informed the dosing regimen. The primary endpoint of CLARITY AD was change from baseline on the Clinical Dementia Rating–Sum of Boxes score, with key secondary endpoints including assessments like the Alzheimer's Disease Assessment Scale–Cognitive Subscale and the Alzheimer's Disease Cooperative Study–Activities of Daily Living scale. Results demonstrated a statistically significant slowing of clinical decline compared to placebo, leading to the accelerated and subsequent traditional approval by the U.S. Food and Drug Administration.

Adverse effects

The most common adverse reactions associated with lecanemab infusion include amyloid-related imaging abnormalities (ARIA), which typically present as temporary swelling or microhemorrhages in the brain detected on magnetic resonance imaging. Other frequent events involve infusion-related reactions such as fever, flu-like symptoms, nausea, and vomiting. Serious risks include symptomatic ARIA-E (edema) and ARIA-H (hemosiderin deposition), with warnings highlighted in the prescribing information from the U.S. Food and Drug Administration. The incidence of ARIA is higher in carriers of the apolipoprotein E ε4 allele, a known genetic risk factor for Alzheimer's disease.

Society and culture

The approval of lecanemab, marketed as Leqembi, has generated substantial discussion within the medical community, patient advocacy groups like the Alzheimer's Association, and health policy circles. Its high annual cost has sparked debates about Medicare coverage, healthcare economics, and equitable access to innovative therapies. The drug's development by Eisai and Biogen represents a major commercial and research investment in the field of neurodegenerative disease. Its arrival has also intensified ethical and practical conversations around early diagnosis, biomarker testing, and the infrastructure required for administering infusion-based therapies in memory clinics.

Chemistry

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody produced in Chinese hamster ovary cells using recombinant DNA technology. Its primary structure consists of two heavy chains and two light chains with a total molecular weight of approximately 55.2 kilodaltons. The antibody is formulated as a sterile, preservative-free solution for intravenous infusion, typically supplied in single-dose vials. The drug substance is designed to be stable under specific storage conditions as defined by the manufacturer, Eisai.

Category:Monoclonal antibodies Category:Alzheimer's disease medications Category:Biogen Category:Eisai